Onconic Therapeutics Inc.
Research Onconic Therapeutics Inc. (476060.KQ) on Bullrun: market cap KRW 631.17B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker476060.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyKRW
- Market capKRW 631.17B
- Financial periodQ2 2026
- RevenueKRW 24.40B
- Net incomeKRW 3.77B
- Free cash flowKRW 3.59B
- Gross margin100.0%
Valuation Snapshot
latest market cap is KRW 631.17B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 631.17B | n/a | n/a | n/a |
Dividend history
About Onconic Therapeutics Inc.
Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Onconic Therapeutics Inc.'s market cap?
Onconic Therapeutics Inc.'s market capitalization is KRW 631.17B.
What does Onconic Therapeutics Inc. do?
Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. The company was founded in 2020 and is based in Seoul, South Korea.